Codelac neo drops vn.pr. 5mg / ml-20ml vial cap.

Description

Composition
Active substance:
Butamirata citrate (in terms of 100% substance) – 100 mg ;.
Excipients:
Sorbitol (Neosorb 70/70 B, sorbitol syrup) – 8100 mg, glycerol (glycerin) – 5800 mg, 95% ethanol (ethyl alcohol 95%) – 61 mg Sodium saccharinate – 23 mg, benzoic acid – 23 mg of vanillin – 23 mg of sodium hydroxide solution 30% – 10 mg purified water to 20 mL.
Description:
The liquid from colorless to colorless to yellowish white, transparent or opalescent light, vanilla odor.
Product form:
Drops for oral administration of 5 mg / ml.
20 ml vials dropper dark (amber) glass. One vial together with instructions for use in a pile of cardboard.
Contraindications
Increased sensitivity to the drug, fructose intolerance, pregnancy (I term), during breastfeeding. Children under the age of 2 months.
Carefully
Pregnancy (II and III trimester).
Due to the presence of ethyl alcohol drug used with caution in patients with a propensity for the development of drug dependency, with liver disease, alcoholism, epilepsy, brain disease, pregnant women and children.
Dosage
5 mg / ml
Indications
Dry cough of any etiology, including whooping cough; cough suppressants in the preoperative and postoperative surgical interventions and bronchoscopy.
Interaction with other drugs
Any drug interactions are not described for butamirata. In the period of treatment is not recommended to drink alcohol, and drugs that suppress the central nervous system (hypnotics, neuroleptics, tranquilizers and other drugs).
Due to the fact that butamirata suppresses the cough reflex, avoid simultaneous use of expectorants to avoid accumulation of mucus in the airways of the risk of bronchospasm and respiratory tract infections.
Overdose
Symptoms include nausea, vomiting, drowsiness, diarrhea, dizziness, decreased blood pressure, impaired coordination of movements.
Treatment: activated charcoal, saline laxatives, symptomatic therapy (if indicated).
pharmachologic effect
Pharmacological group:
Antitussive central action.
Pharmacodynamics:
Butamirata, active agent formulation Codelac® NEO is a centrally acting antitussive. Does not apply to opium alkaloids do not chemically or pharmacologically. It does not produce dependence or addiction.
Suppresses cough, having a direct effect on the cough center. It has bronchodilatory effect (expands bronchi). It helps to alleviate respiratory spirometry improves (reduces airway resistance) and blood oxygenation (saturates the blood with oxygen).
Pharmacokinetics:
Suction
After ingestion butamirata rapidly and completely absorbed from the gastrointestinal tract. After receiving 150 mg butamirata maximum concentration of the main metabolite (2-phenylbutyric acid) in plasma is achieved after about 1.5 hours and is 6.4 .mu.g / ml.
Distribution and metabolism
Hydrolysis butamirata initially to 2-phenylbutyric acid and dietilaminoetoksietanola starts in blood. These metabolites also possess antitussive activity, and, like butamirata largely (about 95%) bind to plasma proteins, which leads to their long half-life. 2-phenylbutyric acid is partially metabolized by hydroxylation.
Repeated dose drug accumulation was observed.
breeding
The half-life butamirata – 6 hours. Metabolites are excreted primarily by the kidney. Moreover, 2-phenylbutyric acid mostly appears in the associated form of glucuronic acid.
Pregnancy and breast-feeding
No safety data, use during pregnancy, and it passes through the placental barrier. Use of the drug in the first trimester of pregnancy is contraindicated. In II and III trimester of pregnancy, the use of the drug is possible, taking into account the ratio of benefits to the mother and the potential risk to the fetus.
The penetration of the drug into breast milk has not been studied, so the use of the drug during breast feeding is not recommended.
Conditions of supply of pharmacies
Without recipe.
side effects
Classification of the incidence of adverse reactions: very common (> 1/10); common (> 1/100,
special instructions
Drops contain as sweeteners, sodium saccharinate and sorbitol, therefore it can be applied to patients with diabetes.
Due to the presence of ethyl alcohol preparation, a danger when using the drug in patients with a propensity for the development of drug dependency, with liver disease, alcoholism, epilepsy, brain disease, pregnant women and children.
Effect on driving ability and using machinery:
It is recommended to refrain from driving and other activities potentially hazardous activities that require high concentration and speed of psychomotor reactions, because the drug can cause dizziness, drowsiness.
Storage conditions
At a temperature not exceeding 25 C. Keep out of reach of children.
Dosing and Administration
Inside, the food.
Children aged 2 to 12 months – 10 drops 4 times a day; from 1 year to 3 years – 15 drops 4 times a day; over 3 years – 25 drops 4 times a day.
Before using the drug in children under 2 years of age should consult a doctor.
Drops for oral administration of 5 mg / ml (1 ml contains 22 drops).
If cough persists for more than 5 days after the start of treatment, you should consult a doctor.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist